Latest news
Ocugen Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 06:04:00 GMTOcugen, Inc. 2026: Revenue $1.49M, EPS ($0.07) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 16:21:01 GMTOCGN: Net loss widened on higher R&D and G&A costs, with going concern risk despite improved liquidity - TradingViewTradingView · Thu, 06 Aug 2026 16:18:28 GMTOCGN: FDA cleared phase III for OCU410; cash runway extended to 2028 after $130M financing - TradingViewTradingView · Thu, 06 Aug 2026 14:35:37 GMTOcugen, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:32:00 GMTOcugen reports $1.49M Q2 revenue, $0.07 loss per share and $100.4M cash as of June 30, 2026 - TradingViewTradingView · Thu, 06 Aug 2026 12:33:01 GMTOCGN: FDA cleared OCU410 Phase 3 trial; cash runway extended to 2028 after $130M financing - TradingViewTradingView · Thu, 06 Aug 2026 12:28:27 GMTOCGN Q2'26 Earnings: EPS estimate is (0.05) USD - TradingViewTradingView · Wed, 05 Aug 2026 11:01:34 GMT